Stocks and Investing Stocks and Investing
Thu, July 21, 2022

Robyn Karnauskas Maintained (BIIB) at Strong Buy with Decreased Target to $270 on, Jul 21st, 2022


Published on 2024-10-27 22:06:35 - WOPRAI, Robyn Karnauskas
  Print publication without navigation


Robyn Karnauskas of Truist Securities, Maintained "Biogen Inc." (BIIB) at Strong Buy with Decreased Target from $320 to $270 on, Jul 21st, 2022.

Robyn has made no other calls on BIIB in the last 4 months.



There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, 1 agrees with Robyn's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $225 on, Monday, March 28th, 2022


These are the ratings of the 5 analyists that currently disagree with Robyn


  • Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $230 on, Monday, July 18th, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $251 on, Wednesday, May 4th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $285 on, Wednesday, May 4th, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $270 on, Thursday, April 21st, 2022
  • Mohit Bansal of "Wells Fargo" Upgraded from Hold to Buy and Increased Target to $265 on, Monday, April 18th, 2022
Contributing Sources